BioAge Labs, a US-based developer of medical treatments for ageing-related diseases, has received $90m in series C financing from investors including healthcare provider Kaiser Foundation Hospitals.
Venture capital firm Andreessen Horowitz and entrepreneur Elad Gil co-led the round, which also featured AARP Foundation’s RockCreek Impact Fund, Phi-X Capital and existing investors including Caffeinated Capital, Redpoint Ventures, Pear Ventures, AME Cloud Ventures and Felicis Ventures.
Founded in 2015, BioAge is working on technology intended to counter ageing and age-related diseases by targeting the hypoxia-inducible factor pathway, a protein complex that influences how the body responds to low concentrations of oxygen, the state known as hypoxia.
The funding will support the progress of the company’s first two drug candidates into phase 2 clinical trials for conditions affecting elderly patients, in early 2021.
Andreessen Horowitz led BioAge’s $10.9m series A round in 2017 through its Bio Fund, investing together with Felicis Ventures, AME Cloud Ventures, Pear Ventures, Caffeinated Capital and angel investors including Elad Gil.
The company added $23m in a January 2019 series B round led by Felicis Ventures that took its total funding to $37m. The round was also backed by Andreessen Horowitz, Caffeinated Capital, Pear Ventures, AME Cloud Ventures, Khosla Ventures and Redpoint Ventures.
